TargetBeta
FASN
fatty acid synthase · also FAS, SDR27X1 · Short chain dehydrogenase/reductase superfamily
1 program in company-led studies act on FASN, from 1 company: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| denifanstatrule | Sagimet Biosciences | phase 3 | 152 running | – | NCIt |
Conditions their studies are in
- Acne Vulgaris, 1 program
- Glioblastoma, 1 program
- Neoplasms, 1 program
- Non-alcoholic Fatty Liver Disease, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Aug 2027denifanstat · Sagimet Biosciences · phase 3 · NCT07863193
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.